Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

803

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

April 30, 2015

Conditions
Hypercholesterolemia
Interventions
DRUG

Placebo (for alirocumab)

Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

DRUG

Alirocumab

Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

DRUG

Statin

Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy

Trial Locations (83)

Unknown

Chandler

Goodyear

Carmichael

Fresno

West Hills

Wildomar

Colorado Springs

Golden

Boynton Beach

Jacksonville

Safety Harbor

Atlanta

Boise

Meridian

Chicago

Gurnee

Evansville

Indianapolis

Iowa City

Kansas City

Louisville

Monroe

Auburn

Methuen

Minneapolis

St Louis

Rochester

Farmville

Greensboro

Greenville

Raleigh

Wilson

Cincinnati

Marion

Tulsa

Philadelphia

Wyomissing

Knoxville

Dallas

Houston

San Antonio

Orem

Salt Lake City

South Jordan

Norfolk

Richmond

Spokane

Tacoma

Kenosha

Varna

Sofia

Victoria

Oshawa

Toronto

Woodstock

Montreal

Québec

Trois-Rivières

Budapest

Debrecen

Nyíregyháza

Ajka

Nagykanizsa

Zalaegerszeg

Tel Litwinsky

Safed

Ofakim

Holon

Tel Litwinsky

Skedsmokorset

Oslo

Svidník

Bratislava

Bratislava

Lučenec

Považská Bystrica

Worton Grange, Reading

Edgbaston

Llanishen

Choley

Waterloo

Lloyd Street North

Glasgow

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01926782 - Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) | Biotech Hunter | Biotech Hunter